AnPac Bio-Medical Science Co. Ltd. Receives College Of American Pathologists Accreditation For US Laboratory

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

• AnPac Bio’s clinical laboratories are located in the U.S. and China, with a total of 142 patents issued as of March 2021
• Cancer Differentiation Analysis (“CDA”) technology is AnPac Bio’s approach to early cancer detection and screening technology, with over 200,000 samples and cases to serve as a way of approaching cancer screening
• Company’s ownership percentage in subsidiary AnPai (Shanghai) Healthcare Management Consultant Co. Ltd. has increased from 20% to 60%, following rigorous regulatory assessments and audits

With a focus on early cancer screening and detection, biotechnology company AnPac Bio-Medical Science ANPC recently announced that its U.S. laboratory has received accreditation from the College of American Pathologists (“CAP”). The U.S. federal government recognizes the CAP Laboratory Accreditation Program as equivalent to or more stringent than the government’s inspection program for laboratories. The accreditation from CAP is considered the gold standard for laboratories of this nature (https://ibn.fm/05KFN).

AnPac Bio has clinical laboratories in the U.S. and China, totaling 142 patents issued as of March 2021. The company’s approach for detecting cancer and precancerous diseases is called Cancer Differentiation Analysis (“CDA”) and uses biophysical properties found in the blood to discover changing micro-environments towards cancerous micro-environments before the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Image by felixioncool from Pixabay

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.